Repligen Co. (NASDAQ:RGEN) Given Consensus Rating of “Moderate Buy” by Analysts

Repligen Co. (NASDAQ:RGEN) has been assigned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $186.00.

Several research analysts have recently weighed in on RGEN shares. TD Cowen started coverage on shares of Repligen in a report on Monday. They issued a “buy” rating and a $200.00 price target for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. HC Wainwright dropped their price target on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company.

Repligen Stock Down 2.5 %

NASDAQ:RGEN opened at $145.72 on Thursday. The stock has a market cap of $8.16 billion, a price-to-earnings ratio of -393.83, a PEG ratio of 4.54 and a beta of 0.99. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average price of $155.45 and a two-hundred day moving average price of $149.14. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the business earned $0.23 EPS. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, equities analysts expect that Repligen will post 1.54 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

Large investors have recently made changes to their positions in the stock. ExodusPoint Capital Management LP raised its position in Repligen by 122.8% during the fourth quarter. ExodusPoint Capital Management LP now owns 213,718 shares of the biotechnology company’s stock worth $30,763,000 after acquiring an additional 117,787 shares in the last quarter. Westpac Banking Corp raised its holdings in shares of Repligen by 17.9% in the 4th quarter. Westpac Banking Corp now owns 21,725 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 3,305 shares during the period. Cinctive Capital Management LP lifted its stake in Repligen by 717.1% in the 4th quarter. Cinctive Capital Management LP now owns 61,398 shares of the biotechnology company’s stock valued at $8,838,000 after purchasing an additional 53,884 shares during the last quarter. Groupama Asset Managment grew its holdings in Repligen by 12,321.0% during the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after purchasing an additional 400,680 shares during the period. Finally, Alliancebernstein L.P. increased its position in Repligen by 23.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock worth $145,508,000 after buying an additional 191,439 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.